Latest Breaking News On - Recurrent respiratory papillomatosis - Page 8 : vimarsana.com

Share this article Share this article PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/  INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIO s management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss financial results and provide a general business update, including: top-line efficacy data from REVEAL 1, a Phase 3 clinical trial of VGX-3100; a progress update for the company s INNOVATE Phase 2/3 COVID-19 vaccine clinical trial and its development strategy regarding the new COVID-19 vaccine addressing the current and future COVID variants of concern (VOC); and a general update on its DNA medicines platform. The live webcast and a replay may be accessed by visiting INOVIO s website at http://ir.inov

United statesHong kongUnited kingdomSouth africaMacau generalSouth africanBen matoneJeff richardsonKaneka eurogentecJ joseph kimWalter reed army institute of researchUs department of defenseNational cancer instituteNational institute of allergyUs department of defense doPlumbline life sciences